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1	 Subjective	effects	are	the	most	objective	biomarkers	to	study	the	effects		
of	cannabis (this thesis)
2	 Progress	in	cannabinoid	research	is	obstructed	by	an	excessive	variety		
of	tests	(this thesis)
3	 The	Volcano®	vaporizer	is	a	reproducible,	practical,	and	well-tolerated		
mode	of	intrapulmonary	thc	administration	with	reliable	pharmacokinetic	
and	pharmacodynamic	time	profiles (this thesis)
4	 Antagonizing	thc-induced	effects	is	a	useful	way	to	study	the	central		
nervous	system	effects	of	a	cb1	antagonist (this thesis)
5	 For	the	development	of	cannabinoids	in	general	it	is	worthwhile	to	unravel	
the	complex	cardiovascular	mechanisms	in	humans	since	cardiovascular		
side	effects	(tachycardia,	hypotension)	are	a	limitation	for	their	therapeutic	
use	 (this thesis)
6	 The	route	of	administration	is	a	decisive	factor	in	causing	unpleasant		
central	nervous	system	effects	by	cb1/cb2	agonists (this thesis)
7	 Regarding	sedation	and	heart	frequency,	animal	models	do	not		
accurately	predict	cb1	agonist	activity	in	humans (this thesis)
8	 Cannabis	research	cannot	bear	daylight	
9	 Walking	on	the	edge	gives	the	best	views	and	insights
10	 Trying	to	understand	the	brain	is	a	humbling	experience
11	 The	brain	is	a	brilliant	idea
12	 The	truth	is	in	the	details
